JPMorgan Chase Reduces Stake in Incyte Corporation

Institutional investor sold 384,394 shares of the biopharmaceutical company in the third quarter.

Mar. 22, 2026 at 8:49am

Got story updates? Submit your updates here. ›

JPMorgan Chase & Co. reduced its stake in Incyte Corporation (NASDAQ:INCY) by 46.2% in the third quarter, according to a recent filing with the Securities & Exchange Commission. The institutional investor now owns 447,720 shares of the biopharmaceutical company's stock, down from 832,114 shares previously.

Why it matters

Incyte is a prominent biopharmaceutical company focused on developing novel therapies for cancer, autoimmune disorders, and rare diseases. JPMorgan Chase's reduced stake in the company could signal a shift in investor sentiment or portfolio strategy, which may impact Incyte's stock performance and future growth prospects.

The details

According to the filing, JPMorgan Chase sold 384,394 shares of Incyte during the third quarter, reducing its ownership to 0.23% of the company's outstanding shares. The institutional investor cited the sale as part of its regular portfolio management activities.

  • JPMorgan Chase & Co. filed the report on March 22, 2026, detailing its third-quarter 2025 transactions.
  • The sale of Incyte shares occurred during the third quarter of 2025.

The players

JPMorgan Chase & Co.

A multinational investment bank and financial services company headquartered in New York City.

Incyte Corporation

A biopharmaceutical company focused on the discovery, development, and commercialization of novel therapies in oncology and inflammation.

Got photos? Submit your photos here. ›

The takeaway

JPMorgan Chase's reduced stake in Incyte Corporation could signal a shift in investor sentiment towards the biopharmaceutical company, which may impact its stock performance and future growth prospects. However, the sale appears to be part of the institutional investor's regular portfolio management activities, rather than a significant strategic move.